Cyril Touboul

Dr. Cyril Touboul

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JHJessica Hoarau-Véchot
Jessica Hoarau-Véchot
ATArash Rafii Tabrizi
Arash Rafii Tabrizi
CTCyril Touboul
Cyril Touboul
JPJennifer Pasquier
Jennifer Pasquier
An area that has come to be of tremendous interest in tumor research in the last decade is the role of the microenvironment in the biology of neoplastic diseases. The tumor microenvironment (TME) comprises various cells that are collectively important for normal tissue homeostasis as well as tumor progression or regression. Seminal studies have demonstrated the role of the dialogue between cancer cells (at many sites) and the cellular component of the microenvironment in tumor progression, metastasis, and resistance to treatment. Using an appropriate system of microenvironment and tumor culture is the first step towards a better understanding of the complex interaction between cancer cells and their surroundings. Three-dimensional (3D) models have been widely described recently. However, while it is claimed that they can bridge the gap between in vitro and in vivo, it is sometimes hard to decipher their advantage or limitation compared to classical two-dimensional (2D) cultures, especially given the broad number of techniques used. We present here a comprehensive review of the different 3D methods developed recently, and, secondly, we discuss the pros and cons of 3D culture compared to 2D when studying interactions between cancer cells and their microenvironment.

26 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SBSofiane Bendifallah
Sofiane Bendifallah
SSStephane Suisse
Stephane Suisse
APAnne Puchar
Anne Puchar
LDLéa Delbos
Léa Delbos
MPMathieu POILBLANC
Mathieu POILBLANC
EDEmile Darai
Emile Darai
Background: Endometriosis diagnosis constitutes a considerable economic burden for the healthcare system with diagnostic tools often inconclusive with insufficient accuracy. We sought to analyze the human miRNAome to define a saliva-based diagnostic miRNA signature for endometriosis. Methods: We performed a prospective ENDO-miRNA study involving 200 saliva samples obtained from 200 women with chronic pelvic pain suggestive of endometriosis collected between January and June 2021. The study consisted of two parts: (i) identification of a biomarker based on genome-wide miRNA expression profiling by small RNA sequencing using next-generation sequencing (NGS) and (ii) development of a saliva-based miRNA diagnostic signature according to expression and accuracy profiling using a Random Forest algorithm. Results: Among the 200 patients, 76.5% (n = 153) were diagnosed with endometriosis and 23.5% (n = 47) without (controls). Small RNA-seq of 200 saliva samples yielded ~4642 M raw sequencing reads (from ~13.7 M to ~39.3 M reads/sample). Quantification of the filtered reads and identification of known miRNAs yielded ~190 M sequences that were mapped to 2561 known miRNAs. Of the 2561 known miRNAs, the feature selection with Random Forest algorithm generated after internally cross validation a saliva signature of endometriosis composed of 109 miRNAs. The respective sensitivity, specificity, and AUC for the diagnostic miRNA signature were 96.7%, 100%, and 98.3%. Conclusions: The ENDO-miRNA study is the first prospective study to report a saliva-based diagnostic miRNA signature for endometriosis. This could contribute to improving early diagnosis by means of a non-invasive tool easily available in any healthcare system.

31 January 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CTCyril Touboul
Cyril Touboul
RLRaphael Lis
Raphael Lis
HFHalema Al Farsi
Halema Al Farsi
CRChristophe Raynaud
Christophe Raynaud
MWMohamed Warfa
Mohamed Warfa
ATArash Rafii Tabrizi
Arash Rafii Tabrizi
The early peritoneal invasion of epithelial ovarian cancer (EOC) by tumoral aggregates presents in ascites is a major concern. The role of the microenvironment seems to be important in this process but the lack of adequate models to study cellular interactions between cancer cells and stromal cells does not allow to uncover the molecular pathways involved. Our goal was to study the interactions between ovarian cancer cells (OCC) and mesenchymal stem cells (MSC) using a 3D model.

19 February 2018 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
JPJennifer Pasquier
Jennifer Pasquier
MGMarie Gosset
Marie Gosset
CGCaroline Geyl
Caroline Geyl
JHJessica Hoarau-Véchot
Jessica Hoarau-Véchot
ACAudrey Chevrot
Audrey Chevrot
CTCyril Touboul
Cyril Touboul
Minimal residual disease is the main issue of advanced ovarian cancer treatment. According to the literature and previous results, we hypothesized that Mesenchymal Stromal Cells (MSC) could support this minimal residual disease by protecting ovarian cancer cells (OCC) from chemotherapy. In vitro study confirmed that MSC could induce OCC chemoresistance without contact using transwell setting. Further experiments showed that this induced chemoresistance was dependent on IL-6 OCC stimulation. We combined meticulous in vitro profiling and tumor xenograft models to study the role of IL-6 in MSC/OCC intereactions. We demonstrated that Tocilizumab® (anti-IL-6R therapy) in association with chemotherapy significantly reduced the peritoneal carcinosis index (PCI) than chemotherapy alone in mice xenografted with OCCs+MSCs. Further experiments showed that CCL2 and CCL5 are released by MSC in transwell co-culture and induce OCCs IL-6 secretion and chemoresistance. Finally, we found that IL-6 induced chemoresistance was dependent on PYK2 phosphorylation. These findings highlight the potential key role of the stroma in protecting minimal residual disease from chemotherapy, thus favoring recurrences. Future clinical trials targeting stroma could use anti-IL-6 therapy in association with chemotherapy.

1 January 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
CBClaire Bonneau
Claire Bonneau
RRRoman Rouzier
Roman Rouzier
CGCaroline Geyl
Caroline Geyl
ACAnnie Cortez
Annie Cortez
MCMathieu Castela
Mathieu Castela
CTCyril Touboul
Cyril Touboul

4 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KKKamila Kolanska
Kamila Kolanska
SBSofiane Bendifallah
Sofiane Bendifallah
GCGeoffroy Canlorbe
Geoffroy Canlorbe
AMArsene Mekinian
Arsene Mekinian
CTCyril Touboul
Cyril Touboul
EDEmile Darai
Emile Darai
The molecular responses to hormonal stimuli in the endometrium are modulated at the transcriptional and post-transcriptional stages. Any imbalance in cellular and molecular endometrial homeostasis may lead to gynecological disorders. MicroRNAs (miRNAs) are involved in a wide variety of physiological mechanisms and their expression patterns in the endometrium are currently attracting a lot of interest. miRNA regulation could be hormone dependent. Conversely, miRNAs could regulate the action of sexual hormones. Modifications to miRNA expression in pathological situations could either be a cause or a result of the existing pathology. The complexity of miRNA actions and the diversity of signaling pathways controlled by numerous miRNAs require rigorous analysis and findings need to be interpreted with caution. Alteration of miRNA expression in women with endometriosis has been reported. Thus, a potential diagnostic test supported by a specific miRNA signature could contribute to early diagnosis and a change in the therapeutic paradigm. Similarly, specific miRNA profile signatures are expected for RIF and endometrial cancer, with direct implications for associated therapies for RIF and adjuvant therapies for endometrial cancer. Advances in targeted therapies based on the regulation of miRNA expression are under evaluation.